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The prognosis for gastric cancer with liver metastasis
continues to be poor. We present our preliminary findings
from 4 cases of liver metastasis from gastric adenocarcinomas
treated using radiofrequency ablation (RFA). Between 1995
and 2004, the clinical history and course of 4 patients who
underwent radiofrequency ablation for liver metastases from
gastric cancer were reviewed. Two patients with smaller
metachronous metastasis are currently alive without recurrence
at 16 and 14 months and the other patients with larger synchr-
onous metastatic lesions died after 4 and 12 months after RFA.
Although this study was limited to a few cases and had a short
follow-up duration, our findings suggest that RFA may
provide an alternative treatment modality for liver metastasis
resulting from gastric adenocarcinoma. Additional study is
needed with a larger group of patients and longer follow up
to evaluate the efficacy of RFA.
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INTRODUCTION
Although there have been reports of long term
survival after liver resection for liver metastasis
from gastric adenocarcinoma, the prognosis for
most cases remains poor and there is no esta-
blished and effective management.
1,2 Radiofrequ-
ency ablation (RFA) has become a popular alterna-
tive to surgery for tumor ablation due to its safety,
availability and wide applicability to primary or
secondary hepatic malignancies.
3-5 However, the
treatment efficacy of RFA for liver metastasis from
gastric cancer remains unknown; only a few small
series have been reported to date.
6,7 Here we
report our findings using RFA for liver metastasis
from gastric cancer in four cases.
CASE REPORT
Case 1
A 72-year-old man who presented with inter-
mittent melena for a month was admitted to our
hospital. He had a past medical history of myocar-
dial infarction with congestive heart failure.
Endoscopic examination and upper gastrointesti-
nal series revealed a Borrmann type II tumor
involving the greater curvature of the lower third
to antrum of the stomach. Abdominal computed
tomography (CT) showed a mass encircling the
gastric antrum with perigastric fat infiltration and
regional lymph node enlargement. There was no
distant metastasis noted. Radical subtotal gastrec-
tomy with Billroth-I reconstruction was performed
in April 2002. The final pathology demonstrated
a 5.5 × 5 cm papillary adenocarcinoma with no
lymphovascular or neural involvement. The tumor
was staged as pT2N0M0 (stage Ib) according to the
sixth edition of the UICC TNM classification.
8 The
patient was discharged at postoperative day eight
without postoperative morbidity. Adjuvant che-
motherapy with oral 5-fluorouracil was admini-
stered. Forty months after surgery, the follow-up
endoscopic examination revealed no tumor recur-
rence in the gastric remnant, but diffuse hyperemic
and edematous mucosa was noted. Follow-up
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CT performed at the same time uncovered a 1.7
× 1.5 cm ill-defined low attenuated lesion on the
left lateral segment of the liver. Liver ultrasono-
graphy revealed a solid mass at the subcapsular
area in segment III which was confirmed to be a
metastatic adenocarcinoma by liver biopsy. RFA,
using 3 cm internally cooled electrodes (Cool-tip;
Radionics Corporation; Burlington, MA, USA) was
performed percutaneously with ultrasound gui-
dance for 12 minutes at 100 C under local anes-
thesia. There were no complications after RFA. A
CT scan obtained two months after RFA showed
that the area of the tumor was completely coagu-
lated and necrotic (Fig. 1). Chemotherapy with
TS-1 was administered after RFA. The patient is
still alive without intrahepatic or local recurrence
16 months after RFA.
Case 2
A 62-year-old man who had undergone radical
subtotal gastrectomy with Billroth-I reconstruction
in March 2003 and had a 3.5 × 3 cm well-differ-
entiated adenocarcinoma classified as pT3N0M0
(stage II) confirmed 30 months previously was
admitted to our hospital for the evaluation of a
hepatic mass. There were two masses noted at
segment IV (2.4 cm) and VI (2.3 cm) of the liver
which were confirmed to be well-differentiated
adenocarcinomas. Under local anesthesia, ultra-
sound-guided percutaneous RFA using 3 cm inter-
nally cooled electrodes (Cool-tip) was performed
for each lesion for six and ten minutes. Three
months later, a follow up CT scan showed no
viable tumor or new lesions (Fig. 2). The patient
received no adjuvant therapy and is alive without
local or distant recurrence 15 months after RFA.
Case 3
A 37-year-old man who had been diagnosed
with gastric cancer at a local clinic was admitted
to our hospital presenting with intermittent
cramping abdominal pain for three months in
April 1999. The endoscopy, upper gastrointestinal
series and abdominal CT revealed a Borrmann
type II gastric cancer located in the lower body of
the stomach without any evidence of metastatic
disease. He underwent radical subtotal gastrec-
tomy with Billroth-II reconstruction. The patho-
logical findings confirmed the diagnosis of an 8.5
× 8.5 cm ulcerofungating mass composed of undif-
ferentiated adenocarcinoma. There were no lym-
phovascular tumor emboli and there was no neural
invasion. The cancer was staged as pT2N1M0
(stage II) according to the sixth edition of the UICC
TNM classification system. Three months after
surgery, follow-up CT revealed a 6.2 × 4 cm liver
metastasis at segment VIII. Liver biopsy was
performed and microscopic findings revealed an
undifferentiated adenocarcinoma compatible with
a metastatic tumor. RFA was performed percu-
Fig. 1. Case 1: Radiofrequency ablation of a hepatic metastasis from gastric cancer. (A) Preprocedural CT scan revealing
a 1.7 cm sized liver metastasis in segment III. (B) CT scan 2 months after RFA showing complete tumor ablation.
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taneously because the patient did not want to
undergo liver resection. A 50-watt monopolar RF
generator (model 500 series; Radiofrequency Inter-
stitial Thermal Ablation Medical System, Mountain
View, CA, USA) and an active expandable RF
needle electrode with 7 retractable lateral prongs
were used. A needle probe with a 7-deployable
array was inserted into the tumor under ultra-
sound guidance. Coagulation, 6 times for 10 minutes
each, was performed at 100 C. Near the portal
vein, coagulation for 7 minutes at 90 C was per-
formed. One month later, follow-up liver CT scan
indicated that the mass was larger with hetero-
geneous enhancement, suggesting a viable tumor
Fig. 2. Case 2: Radiofrequency ablation of hepatic metastases from gastric cancer. (A-1) Preprocedural CT scan showing
a 2.4 cm sized hepatic mass in segment IV. (A-2) Preprocedural CT scan showing a 2.3 cm sized hepatic mass in segment
VI. (B-1 and B-2) CT scans one month after RFA. Both metastatic lesions in segments IV and VI were completely ablated.
Fig. 3. Case 3: Radiofrequency ablation of a hepatic metastasis from gastric cancer. (A) Preprocedural computed
tomography (CT) scan revealing a 6.2 cm sized hepatic metastasis in segment VIII. (B) CT scan obtained one month after
RFA of tumor. The hepatic metastasis is larger and shows heterogeneous enhancement.
A-1
A-2
B-1
B-2
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and portal vein thrombosis (Fig. 3). The patient
died four months after RFA.
Case 4
A 53-year-old man underwent radical subtotal
gastrectomy with Billroth-I reconstruction in
March 2000 and was diagnosed with a pT2N1M0
(stage II), 3.5 × 3 cm, poorly-differentiated adeno-
carcinoma. Nine months later, he returned with
liver metastasis at segment VII. Liver biopsy
confirmed a metastatic adenocarcinoma. After five
cycles of chemotherapy with taxotere and cisplatin
over five months there was no change in the 4 cm
hepatic mass. A percutaneous RFA using a 3 cm
internally cooled electrode (Cool-tip) was perfor-
med twice for 12 minutes at 100 C. There were no
RFA-related complications. The patient received
chemotherapy with irinotecan, leucovorin and
5-fluorouracil. A CT scan performed one month
after RFA showed a hypodense lesion without
contrast enhancement consistent with complete
ablation and no residual intrahepatic metastases
(Fig. 4). Four months after the RFA, however,
multiple new liver metastases were detected. The
patient died one year after RFA.
DISCUSSION
Liver metastasis is one of the most frequent
forms of hematogenous spread of gastric cancers;
the proportion of gastric cancers metastasizing to
the liver ranges from 3.7% to 11%.
2,9,10 Most cases
of liver metastases from gastric cancer involve both
lobes of the liver and are accompanied by perito-
neal dissemination, extensive lymph node metas-
tases or direct invasion to adjacent organs.
11,12 The
rate of hepatic resection in such cases ranges from
only 0.5% to 2.3%.
2,9,10 Moreover, the survival
outcomes for hepatic resection of gastric cancer
liver metastases have been unsatisfactory,
13,14
although there have been isolated reports of long-
term improved survival after aggressive surgical
treatments for this disease in highly selected
patients.
9,15-17
RFA has been used for the treatment of primary
and secondary hepatic malignancies, especially in
hepatocellular carcinoma and colorectal cancer,
and has provided a safe and effective alternative
for unresectable tumors.
3,5,18 RFA can eliminate
tumors with minimal injury to the surrounding
hepatic parenchyma, and percutaneous, laparo-
Fig. 4. Case 4: Radiofrequency ablation of a hepatic meta-
stasis from gastric cancer. (A) Preprocedural CT scan dis-
playing a 4 cm sized hepatic metastasis in segment VII.
(B) CT scan one month after RFA. A hypodense lesion
without contrast enhancement covers the site of metas-
tasis. (C) CT scan obtained after four months after RFA
showing slight enhancement on the margin of the tumor
and multiple hepatic metastases.
A
B
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scopic and open surgical approaches have all been
proven to be safe.
19 The reported therapeutic res-
ponse rate is 66% for metastatic colorectal cancer.
18
Tumor control rates at one year have reached 94%
and 90% for intraoperative and percutaneous RFA,
respectively.
20 However, there have only been a
few reports on the results of RFA therapy used for
liver metastasis from gastric cancer.
6,7,21 Based on
these considerations, we applied RFA to liver
metastasis from gastric cancer without extra-
hepatic metastasis.
In April 1999, we started RF ablations for hepatic
tumors in our institution. We used four kinds of
commercially available RF devices manufactured
by three different companies. Among them, two
RF devices were used in our study. We selected
the type of devices on a case-by-case basis, de-
pending on the availability of the electrodes in
stock and the size and location of the tumors. Our
strategy during RFA was to include a peripheral
margin of 0.5-1.0cm of normal hepatic parenchyma
surrounding the tumor as well as the entire tumor
itself, regardless of the RF device used or the size
of the tumor. According to manufacturers' recom-
mendations, we usually ablated a small (less than
3 cm in diameter) hepatic tumor for 12 minutes
with either a set power or target temperature.
However, we sometimes decreased the ablation
time when injury of the adjacent organs or blood
vessels was a concern. For tumors larger than 3cm
in diameter, whenever possible, we performed
multiple overlapping ablations.
Zacherl et al. reported that curative resection for
metachronous liver metastases might allow long-
term survival in selected patients.
15 In addition, Rho
et al. reported that the median survival for
metachronous hepatic metastases was better than
that of synchronous metastases (74.3 months vs.
13.0 months), and that surgical management
should be considered for solitary hepatic lesions
as a treatment option.
17 In our cases, both of the
patients with synchronous metastasis (cases 3 and
4) showed poor therapeutic response after RFA,
whereas the therapeutic response to RFA for cases
1 and 2 was relatively favorable. These findings
are in agreement with the above reports despite
the short follow-up. Therefore, accurate evaluation
for the presence of liver metastasis preoperatively
is important to predict patient prognosis and to
determine the treatment plan. In these four cases,
we performed a preoperative CT scan, which can
readily detect the presence of visceral metastatic
diseases, and no patient has evidence of liver
metastasis. However, the accuracy of diagnosis in
the patient discussed in case 3 in whom follow-up
CT revealed a liver metastasis three months after
surgery is questionable.
The size of the hepatic metastasis to be treated
is the most important factor in determining
whether complete local ablation can be achieved.
5
In general, lesions measuring less than 2.5 cm in
diameter have been reported to have a greater than
90% chance of being destroyed, and less than 50%
of tumors measuring greater than 5 cm are likely
to be completely ablated.
5 Gannon et al. recom-
mended not treating tumors > 5 cm in maximal
diameter with RFA.
19 The tumor sizes in our cases
ranged from 1.7 to 6.2 cm. The hepatic lesions were
smaller in cases 1 and 2 than in cases 3 and 4. In
case 3, RFA was performed six times due to the
large size (6.2 cm) of the tumor and its location
next to an adjacent major vessel, but successful
tumor control was still not achieved.
The number of tumors present is another
significant prognostic factor in patients with liver
metastasis. Gannon et al. reported that tumor
biology and behavior indicate that it is unlikely
that RFA would be effective for more than five
metastases with regard to a survival benefit for
patients.
19 Shirabe et al. reported that the presence
of more than three hepatic metastases was an
independent poor prognostic factor based on
observations in patients after hepatic resection of
liver metastasis from gastric cancer.
22 Three patients
in our sample had a solitary liver metastasis while
one had two lesions. Further study is needed to
compare the outcome of patients according to the
number of metastatic lesions in the liver.
With improvements in ablation techniques and
instruments, the number and extent of RFA treat-
ments is increasing. However the efficacy, indica-
tions and limitations of this therapy for liver
metastasis from gastric adenocarcinomas have not
been studied in a large series of patients to date.
In our small number of cases, the complementary
role of RFA as a modality of treatment for hepatic
metastasis from gastric cancer should be con-
sidered as an option for such patients. FurtherRFA for Gastric Cancer Liver Metastasis
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evaluation is needed to determine the appropriate
inclusion criteria for RFA and to achieve improved
survival benefits. In addition, study of survival
benefits with RFA compared to hepatic resection
should be pursued.
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